Impact of first-line bevacizumab (BV) on the clinical outcomes of patients with metastatic colorectal cancer (mCRC) treated with second-line FOLFIRI plus BV

被引：0
|
作者：
Muro, Kei
Yamanaka, Takeharu
Suenaga, Mitsukuni
Nishina, Tomohiro
Yasul, Hisateru
Ura, Takashi
Denda, Tadamichi
Ikeda, Junichi
Esakl, Taito
Nishisaki, Hogara
Takano, Yoshinao
Kondo, Ken
Takeda, Koji
Takahashi, Yasuo
Endo, Kazuya
Sugiyama, Yasuyuki
机构：
[1] Aichi Canc Ctr Hosp, Dept Clin Oncol, Nagoya, Aichi 464, Japan
[2] Natl Canc Ctr, Tokyo 104, Japan
[3] Japanese Fdn Canc Res, Canc Inst Hosp, Dept Gastroenterol, Tokyo, Japan
[4] Natl Hosp Org Shikoku Canc Ctr, Dept Gastroenterol, Matsuyama, Ehime, Japan
[5] Natl Hosp Org Kyoto Med Ctr, Dept Med Oncol, Kyoto, Japan
[6] Chiba Canc Ctr, Div Gastroenterol, Chiba 2608717, Japan
[7] Japanese Red Cross Kitami Hosp, Dept Surg, Kitami, Hokkaido, Japan
[8] Kyushu Natl Canc Ctr, Dept Gastrointestinal & Med Oncol, Fukuoka, Japan
[9] Hyogo Canc Ctr, Dept Gastrointestinal & Hepato Biliary Oncol, Akashi, Hyogo, Japan
[10] Southern Tohoku Gen Hosp, Dept Surg, Koriyama, Fukushima, Japan
[11] Natl Hosp Org Nagoya Med Ctr, Dept Surg, Nagoya, Aichi, Japan
[12] Osaka City Gen Hosp, Dept Clin Oncol, Osaka, Japan
[13] Hokkaido Canc Ctr, Dept Gastroenterol, Sapporo, Hokkaido, Japan
[14] Natl Kyushu Med Ctr, Dept Surg, Fukuoka, Japan
[15] Teikyo Univ, Sch Med, Kawasaki, Kanagawa, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.e14565
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e14565
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Effectiveness and Safety of Bevacizumab(BV) plus FOLFIRI as First-Line Metastatic Colorectal Cancer (mCRC) Treatment: ETNA Cohort Study
    Fourrier-Reglat, A.
    Rouyer, M.
    Benichou, J.
    Balestra, A.
    Bernard, M. A.
    Grelaud, A.
    Smith, D.
    Ravaud, A.
    Moore, N.
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2010, 19 : S28 - S28
  • [2] VEGF gene polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab (BV) in metastatic colorectal cancer (mCRC) patients (pts)
    Loupakis, F.
    Ruzzo, A.
    Salvatore, L.
    Canestrari, E.
    Cremolini, C.
    Santini, D.
    Bencardino, K.
    Manzoni, M.
    Falcone, A.
    Graziano, F.
    [J]. EJC SUPPLEMENTS, 2009, 7 (02): : 357 - 357
  • [3] VEGF GENE POLYMORPHISMS IN THE PREDICTION OF BENEFIT FROM FIRST-LINE FOLFIRI PLUS BEVACIZUMAB (BV) IN METASTATIC COLORECTAL CANCER (MCRC) PATIENTS (PTS)
    Loupakis, F.
    Ruzzo, A.
    Salvatore, L.
    Canestrari, E.
    Cremolini, C.
    Masi, G.
    Schirripa, M.
    Spoto, C.
    Galluccio, N.
    Vincenzi, B.
    Santini, D.
    Bencardino, K.
    Ricci, V
    Catalano, V
    Manzoni, M.
    Danova, M.
    Tonini, G.
    Magnani, M.
    Falcone, A.
    Graziano, F.
    [J]. ANNALS OF ONCOLOGY, 2009, 20
  • [4] Prospective evaluation of candidate SNPs of VEGF/VEGFR pathway in metastatic colorectal cancer (mCRC) patients (pts) treated with first-line FOLFIRI plus bevacizumab (BV).
    Cremolini, Chiara
    Loupakis, Fotios
    Yang, Dongyun
    Salvatore, Lisa
    Zhang, Wu
    Wakatsuki, Takeru
    Schirripa, Marta
    Lonardi, Sara
    Antoniotti, Carlotta
    Aprile, Giuseppe
    Masi, Gianluca
    Graziano, Francesco
    Ruzzo, Annamaria
    Lucchesi, Sara
    Ronzoni, Monica
    Maus, Martin Karl Herbert
    Bocci, Guido
    Tonini, Giuseppe
    Falcone, Alfredo
    Lenz, Heinz-Josef
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [5] PROSPECTIVE EVALUATION OF CANDIDATE SNPS OF VEGF/VEGFR PATHWAY IN METASTATIC COLORECTAL CANCER PATIENTS TREATED WITH FIRST-LINE FOLFIRI PLUS BEVACIZUMAB (BV)
    Cremolini, Chiara
    Loupakis, Fotios
    Yang, Dongyun
    Salvatore, Lisa
    Zhang, Wu
    Wakatsuky, Takeru
    Schirripa, Marta
    Lonardi, Sara
    Antoniotti, Carlotta
    Aprile, Giuseppe
    Masi, Gianluca
    Graziano, Francesco
    Ruzzo, Annamaria
    Lucchesi, Sara
    Maus, Martin
    Bocci, Guido
    Falcone, Alfredo
    Lenz, Heinz Joseph
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 105 - 106
  • [6] EFFECTIVENESS AND SAFETY OF FIRST-LINE BEVACIZUMAB PLUS FOLFIRI IN PATIENTS (PTS) WITH METASTATIC COLORECTAL CANCER (MCRC)
    Pinto, Ana Catarina
    Teixeira, Margarida
    Bonito, Nuno
    Jacinto, Paula
    Ribeiro, Joao
    Gervasio, Helena
    [J]. ANNALS OF ONCOLOGY, 2011, 22 : v98 - v98
  • [7] Patients with Metastatic Colorectal Cancer and Hyperbilirubinemia Treated with FOLFIRI plus Bevacizumab as First-Line Treatment
    Huang, Ching-Wen
    Yeh, Yung-Sung
    Ma, Cheng-Jen
    Tsai, Hsiang-Lin
    Chen, Chao-Wen
    Huang, Ming-Yii
    Lu, Chien-Yu
    Wu, Jeng-Yih
    Wang, Jaw Yuan
    [J]. CHEMOTHERAPY, 2017, 62 (01): : 80 - 84
  • [8] Bevacizumab (BV) plus chemotherapy (CT) in second-line metastatic colorectal cancer (mCRC): Initial results from ARIES, a second BV observational cohort study (OCS)
    Bekaii-Saab, T. S.
    Bendell, J. C.
    Cohn, A. L.
    Hurwitz, H.
    Kozloff, M.
    Roach, N.
    Tezcan, H.
    Feng, S.
    Sing, A.
    Grothey, A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [9] Phase Ib study of drozitumab combined with first-line FOLFOX plus bevacizumab (BV) in patients (pts) with metastatic colorectal cancer (mCRC).
    Lima, C. S. Rocha
    Baranda, J. C.
    Wallmark, J.
    Choi, Y.
    Royer-Joo, S.
    Portera, C. C.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [10] Axitinib or bevacizumab (bev) plus FOLFOX or FOLFIRI as second-line therapy in patients (pts) with metastatic colorectal cancer (mCRC)
    Bendell, J. C.
    Tournigand, C.
    Bednarczyk, M.
    Swieboda-Sadlej, A.
    Chung, I.
    Barone, C.
    Tarazi, J. C.
    Rosbrook, B.
    Ricart, A. D.
    Sobrero, A. F.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
12345